Back

Getting real world and “hands on” in patients with elevated LDL-C and high risk features for atherosclerotic cardiovascular disease — Case management sessions.

27 August 2018 (13:35 - 13:55)
Organised by:
Congress Presentation Part of: PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease Lipids Open Access ESC Congress 2018

About the speaker

Photo
Professor Deepak Bhatt

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

4 More presentations in this session

Presentation thumbnail
Chairman’s welcome and introduction: the mandate for improving residual cardiovascular disease risk reduction in patients with adversely elevated LDL-C
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
What do recent landmark, cardiovascular outcome trials evaluating PCSK9 inhibition in high risk patient populations teach us?
Professor P. Steg (Paris, FR)
Slides Video
Presentation thumbnail
Guidelines and the role of non-statin therapies for ASCVD reduction in high risk patients - Addressing statin intolerance and poor target LDL-C goal attainment
Professor J. Jukema (Leiden, NL)
Slides Video
Presentation thumbnail
Interactive question and answer session - PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease.
Professor D. Bhatt (New York City, US)

Access the full session

Session thumbnail
PCSK9 inhibition to prevent and treat atherosclerotic cardiovascular disease

The Event

Event poster

ESC Congress 2018

27 August 2018 13:35 CET
You may be interested in
thumbnail
Congress Presentation
LDL-cholesterol levels post-acute coronary syndrome: 24-months variation
4 April 2025
thumbnail
Congress Presentation
Real-world experiences of dyslipidaemia in patients with high or very high cardiovascular risk.
28 August 2022
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation
The COR Lipid-Registry: The effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources